Article · 2027

Engineered ZFP36-overexpressing AC16 cell-derived extracellular vesicles attenuate ferroptosis-related endothelial injury and functionalize NiTi vascular interfaces

Colloids and Surfaces B: Biointerfaces

Demin Li; Yachen Hou; Yang Lu; Pengchong Du; Ge Zhang; Yan Lv; Ke Hu; Rilige Su; Bolin Jiao; Yangyang Wu; Yujia Wang; Jinying Zhang; Junnan Tang

Cite this paper

Plain citation

Demin Li, Yachen Hou, Yang Lu, Pengchong Du, Ge Zhang, Yan Lv, Ke Hu, Rilige Su, Bolin Jiao, Yangyang Wu, Yujia Wang, Jinying Zhang, Junnan Tang. Engineered ZFP36-overexpressing AC16 cell-derived extracellular vesicles attenuate ferroptosis-related endothelial injury and functionalize NiTi vascular interfaces. Colloids and Surfaces B: Biointerfaces. 2027;270:116261. https://doi.org/10.1016/j.colsurfb.2026.116261

Author-controlled citation; verify against the publisher version of record.

Author evidence note

Principal findings

Vesicles released by ZFP36-overexpressing AC16 cells protected RSL3-challenged human umbilical vein endothelial cells: viability and mitochondrial membrane potential improved, while oxidative stress declined. Direct myocardial administration also improved cardiac function and reduced fibrosis in a mouse infarction model.

Source: Sections 3.3–3.4 and Figures 3–4, pages 6–7 and 9–10; endothelial stress assays and post-infarction outcomes.

Vascular-interface contribution

ZFP36-engineered vesicles were immobilized on polydopamine/hyaluronic-acid-modified NiTi (NPH). The study used nanoparticle tracking analysis (NTA) to measure particle concentrations in the remaining suspension and three PBS washes. It subtracted the recovered particle count from the initial input count, then divided by that input count to estimate 72.80% ± 0.83% loading (mean ± SD, n=3). Over 14 days in PBS at 37 °C, it measured released particles by NTA after collecting and replacing the medium at each time point. Cumulative release was expressed relative to the estimated number initially immobilized. Under RSL3, human umbilical vein endothelial cells (HUVECs) were cultured directly on bare NiTi, NPH without vesicles, NPH with control vesicles and NPH with engineered vesicles. The direct-contact assay also included bare NiTi without RSL3. Live/Dead viable-cell percentages and the oxidized-to-reduced C11-BODIPY fluorescence ratio were measured under these direct-contact conditions. The separate rat femoral-artery injury model compared bare, NPH and engineered-vesicle filaments. At 14 days, the rat study assessed H&E morphology and positive-area staining for CD31, TNF-alpha, OPN, alpha-SMA and 4-HNE. The engineered-vesicle filaments supported endothelial recovery and reduced local inflammatory and lipid-peroxidation-associated signals.

Source: Sections 2.9–2.11, page 3 (particle counts, release denominator, comparison groups and rat assessment); Figure 5G–H and J–M, page 9 (loading, release, direct-contact Live/Dead and C11-BODIPY assays); Figure 6A–H, page 11 and Section 3.6, pages 11–12 (14-day rat morphology and marker-positive areas).

Research use

The cell challenge addresses endothelial protection; the mouse infarction model tests intramyocardial delivery; the rat injury model tests the local vascular interface. Figure 4 reports n=6 for echocardiographic measurements at baseline and 21 days and n=5 for the fibrosis endpoint. The study states that its data are available on request.

Source: Figures 3–4, pages 6–7; Figure 6, page 11; Data availability, page 13. The reported n values refer to their own endpoints, not a pooled study size.

Publication chronology

PubMed records electronic publication on 15 October 2026. The assigned Crossref print record is volume 270, article 116261, February 2027; formal citation exports use 2027. These dates describe one DOI and one study, not two versions of the evidence.

Source: PubMed ArticleDate DateType=Electronic 2026-10-15; Crossref published-print date-parts [2027,2], volume 270 and article-number 116261.

Evidence scope and limitations

Author-maintained explanation of the published preclinical extracellular-vesicle and vascular-interface study. The full article supports separate cell, mouse infarction, and rat arterial-injury experiments.

Provenance

Source review: 2026-11-04.

Author-controlled academic record for Ge Zhang (张格; ORCID 0000-0002-3116-3246). This page identifies the work as part of Ge Zhang’s publication record. It does not replace the publisher version or assert a complete author list.